Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 4509604)

Published in Vaccine on August 12, 2014

Authors

Bethany White1, Annie Madden2, Maria Prins3, Margaret Hellard4, Handan Wand1, Gregory J Dore1, Kimberly Page5, Lisa Maher6

Author Affiliations

1: The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia.
2: Australian Injecting & Illicit Drug Users League (AIVL), Sydney Building, Level 2/112-116 Alinga Street, Canberra ACT 2600, Australia.
3: Academic Medical Centre, Center for Infection and Immunity Amsterdam (CINIMA), University of Amsterdam, The Netherlands; Cluster of Infectious Diseases, Department of Research, Public Health Service, Amsterdam, The Netherlands.
4: Centre for Population Health, The Macfarlane Burnet Institute for Medical Research, 85 Commercial Road, Melbourne, Victoria 3004, Australia.
5: Department of Epidemiology and Biostatistics, University of California San Francisco, 50 Beale Street, Suite 1200, San Francisco, CA 94105, USA.
6: The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia. Electronic address: lmaher@kirby.unsw.edu.au.

Associated clinical trials:

Staged Phase I/II Hepatitis C Prophylactic Vaccine | NCT01436357

Study of a New MVA Vaccine for Hepatitis C Virus | NCT01296451

Articles cited by this

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89

Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44

The global burden of hepatitis C. Liver Int (2009) 8.89

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76

Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol (2001) 2.69

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ (1998) 2.64

Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS (1998) 2.53

Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27

The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction (2012) 2.11

Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust (1997) 2.03

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction (2006) 1.87

Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction (2013) 1.81

High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health (2007) 1.67

High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology (2008) 1.55

Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev (2011) 1.47

Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health (2005) 1.42

Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One (2011) 1.40

Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37

Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr (2000) 1.33

Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28

Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health (2009) 1.25

Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size. Epidemiol Infect (2009) 1.09

Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a canadian setting. Arch Pediatr Adolesc Med (2010) 1.09

Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics (2009) 1.07

Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health (2013) 0.95

The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies. Vaccine (2005) 0.94

Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91

Using ethnographic fieldwork to inform hepatitis C vaccine preparedness studies with people who inject drugs. Int J Drug Policy (2009) 0.87

HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment. Curr Opin HIV AIDS (2012) 0.85

Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs. Drug Alcohol Depend (2011) 0.84

Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs. Drug Alcohol Rev (2012) 0.79